News

Fierce Biotech51m
Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs
Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...